by George Institute for Global Health Credit: Pixabay/CC0 Public Domain The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes. The findings were published in The Lancet Diabetes & Endocrinology. Originally developed to treat diabetes, GLP-1 receptor agonists mimic the...
Tag: <span>Diabetes drugs</span>
Post
Diabetes drug shows promise in protecting kidneys
by Osaka Metropolitan University More red areas in the kidney indicate higher oxygen levels. Credit: Osaka Metropolitan University Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention. An Osaka Metropolitan University-led research group has investigated how such drugs...
Post
Diabetes drugs associated with fewer adverse cardiac events in older veterans
by Vanderbilt University Medical Center Credit: Pixabay/CC0 Public Domain GLP1 receptor agonists—a class of diabetes medications—are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease. The findings, reported in Annals of Internal Medicine, will aid clinicians in choosing a diabetes drug regimen for older...
Post
Class of diabetes drugs cuts dementia risk in older adults, research shows
by Erin Howe, University of Toronto Credit: CC0 Public Domain A class of medication for type 2 diabetes may help older people with the condition reduce their risk of dementia. The findings are contained in a new study by Walter Swardfager, an assistant professor of pharmacology and toxicology at the Temerty Faculty of Medicine and...
Post
Cholesterol and diabetes drugs may lessen risk of degenerative eye disease associated with aging
by British Medical Journal Picture of the back of the eye showing intermediate age-related macular degeneration. Credit: National Eye Institute Regular use of drugs to lower cholesterol and control type 2 diabetes may lessen the risk of the degenerative eye disease associated with aging, known as AMD, finds a pooled data analysis of the available...
Post
Two popular diabetes drugs outperform others in large clinical trial
by National Institute of Diabetes and Digestive and Kidney Diseases Credit: Pixabay/CC0 Public Domain In a large clinical trial that directly compared four drugs commonly used to treat type 2 diabetes, researchers found that insulin glargine and liraglutide performed the best of four medications approved by the U.S. Food and Drug Administration to maintain blood...
Post
New research questions previous link between diabetes drugs and bone fractures
by American Society of Nephrology Graphical abstract: Journal of the American Society of Nephrology (2022). DOI: 10.2215/CJN.16171221 Sodium glucose transport-2 (SGLT-2) inhibitors, which reduce glucose reabsorption by the kidneys, can help control blood sugar levels and protect kidney health in patients with diabetic kidney disease; however, some large clinical trials have linked the medications to a higher...
Post
Diabetes drugs could save thousands of lives
New research has linked two types of less-often prescribed diabetes drugs with lower chances of potentially fatal heart problems – including heart attack, heart failure and stroke – in people with type 2 diabetes without established heart disease. The study of English and Welsh data – led by University of Manchester and Manchester University NHS Foundation Trust (MFT) scientists, is published...
Post
Diabetes drugs could save thousands of lives
New research has linked two types of less-often prescribed diabetes drugs with lower chances of potentially fatal heart problems – including heart attack, heart failure and stroke – in people with type 2 diabetes without established heart disease. The study of English and Welsh data – led by University of Manchester and Manchester University NHS Foundation Trust (MFT) scientists, is published...
Post
Diabetes Drugs Tied to Less Amyloid, Slowed Cognitive Decline in Alzheimer’s
Pauline Anderson August 11, 2021 Among patients with cognitive impairment, those with diabetes who took dipeptidyl peptidase-4 (DPP-4) inhibitors had less amyloid-beta (Aβ) in the brain compared to the patients with diabetes who did not take these medications and to the patients without diabetes, new research shows. DPP-4 inhibitors are a class of oral hypoglycemic agents. The...
- 1
- 2